Syphilis Testing Market Revenue Grows at a CAGR of 11.76%

Straits Research released its highly anticipated report, “Global Syphilis Testing Market Size & Outlook, 2026-2034”. According to the Straits Research, the market size is valued at USD 556.70 million in 2025 and is anticipated to grow to USD 1509.15 million by 2034, growing at a CAGR of 11.76% from 2026-2034.

Market Dynamics

The syphilis testing market is supported by a strong driver in the form of rising participation in community-based screening campaigns that expand routine access to diagnostic services across urban and semi-urban regions. These campaigns increase test uptake among individuals who may not visit clinical facilities regularly, resulting in higher overall use of rapid kits and laboratory assays. A restraint affecting the market is the limited completion of follow-up evaluations after initial screening, as a portion of individuals do not return for confirmatory testing due to scheduling barriers or low awareness of next steps, which reduces the total number of fully assessed cases. An opportunity emerges from the expansion of small community centers dedicated to year-round syphilis awareness and routine walk-in testing, creating consistent access points for screening and strengthening the reach of diagnostic services across diverse neighborhoods.

Market Highlights

• Type: Based on Type, the Primary syphilis segment is anticipated to register the fastest CAGR of 12.12%.
• Test Type: Based on Test Type, Treponemal immunoassays (TPPA, TPHA) segment dominated the market growth with a revenue share of 35.63% in 2025.
• Technology: Based on Technology, the Immunoassay segment dominated the market growth in 2025 with a revenue share of 45.64%.
• Location of Testing: Based on Location of Testing, point-of-care testing segment is anticipated to register the fastest CAGR of 12.67%.
• Regional Insights: North America held a dominant share of the global market, accounting for 42.23% share in 2025.

Market Segments

1. By Type (2026-2034)
   1. Primary Syphilis
   2. Secondary Syphilis
2. By Test Type (2026-2034)
   1. Non-treponemal tests (RPR, VDRL)
   2. Treponemal immunoassays (TPPA, TPHA)
   3. Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA)
   4. Rapid diagnostic tests (lateral flow immunoassays)
   5. Molecular tests (PCR/NAAT)
   6. Multiplex STI panels including syphilis targets
3. By Technology(2026-2034)
   1. Molecular Diagnostics
   2. Immunoassay
   3. Others
4. By Location of Testing(2026-2034)
   1. Laboratory Testing
      1. Commercial/Private Labs
      2. Public Health Labs
   2. Point of Care Testing